$CHRS
Coherus BioSciences, Inc.

2022 Q1 Form 10-Q Financial Statement

#000155837022007420 Filed on May 05, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $60.12M $83.03M
YoY Change -27.6% -28.53%
Cost Of Revenue $9.370M $7.511M
YoY Change 24.75% 9.57%
Gross Profit $50.75M $75.52M
YoY Change -32.81% -30.92%
Gross Profit Margin 84.41% 90.95%
Selling, General & Admin $48.75M $39.39M
YoY Change 23.77% 11.43%
% of Gross Profit 96.07% 52.16%
Research & Development $82.92M $203.5M
YoY Change -59.25% 514.65%
% of Gross Profit 163.4% 269.44%
Depreciation & Amortization $767.0K $800.0K
YoY Change -4.13% 33.33%
% of Gross Profit 1.51% 1.06%
Operating Expenses $131.7M $242.9M
YoY Change -45.79% 222.5%
Operating Profit -$80.93M -$167.4M
YoY Change -51.65% -509.51%
Interest Expense $8.969M $5.648M
YoY Change 58.8% 27.47%
% of Operating Profit
Other Income/Expense, Net $32.00K $61.00K
YoY Change -47.54% -10.29%
Pretax Income -$96.08M -$172.9M
YoY Change -44.44% -573.76%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$96.08M -$172.9M
YoY Change -44.44% -586.19%
Net Earnings / Revenue -159.83% -208.28%
Basic Earnings Per Share -$1.24 -$2.37
Diluted Earnings Per Share -$1.24 -$2.37
COMMON SHARES
Basic Shares Outstanding 77.25M 72.83M
Diluted Shares Outstanding 77.25M 72.83M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $325.7M $399.5M
YoY Change -18.48% 106.67%
Cash & Equivalents $325.7M $259.5M
Short-Term Investments $0.00 $140.0M
Other Short-Term Assets $32.78M $25.70M
YoY Change 27.54% 42.78%
Inventory $36.95M $51.61M
Prepaid Expenses
Receivables $117.0M $140.4M
Other Receivables $0.00 $0.00
Total Short-Term Assets $512.4M $617.3M
YoY Change -16.98% 56.2%
LONG-TERM ASSETS
Property, Plant & Equipment $7.998M $19.10M
YoY Change -58.13% 179.57%
Goodwill $943.0K
YoY Change 0.0%
Intangibles $2.620M
YoY Change 0.0%
Long-Term Investments
YoY Change
Other Assets $9.956M $10.70M
YoY Change -6.95% 2855.8%
Total Long-Term Assets $80.94M $76.04M
YoY Change 6.45% 6.57%
TOTAL ASSETS
Total Short-Term Assets $512.4M $617.3M
Total Long-Term Assets $80.94M $76.04M
Total Assets $593.4M $693.3M
YoY Change -14.41% 48.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $21.09M $15.48M
YoY Change 36.24% -24.42%
Accrued Expenses $45.89M $44.84M
YoY Change 2.35% 129.71%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $107.6M
YoY Change 107500.0%
Total Short-Term Liabilities $153.7M $257.6M
YoY Change -40.32% 116.45%
LONG-TERM LIABILITIES
Long-Term Debt $420.5M $298.9M
YoY Change 40.67% 66.8%
Other Long-Term Liabilities $102.0K $750.0K
YoY Change -86.4% -93.24%
Total Long-Term Liabilities $102.0K $750.0K
YoY Change -86.4% -99.61%
TOTAL LIABILITIES
Total Short-Term Liabilities $153.7M $257.6M
Total Long-Term Liabilities $102.0K $750.0K
Total Liabilities $580.8M $565.6M
YoY Change 2.69% 82.9%
SHAREHOLDERS EQUITY
Retained Earnings -$1.146B -$935.7M
YoY Change 22.47% 8.88%
Common Stock $7.000K $7.000K
YoY Change 0.0% -100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $12.56M $127.7M
YoY Change
Total Liabilities & Shareholders Equity $593.4M $693.3M
YoY Change -14.41% 48.61%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$96.08M -$172.9M
YoY Change -44.44% -586.19%
Depreciation, Depletion And Amortization $767.0K $800.0K
YoY Change -4.13% 33.33%
Cash From Operating Activities -$54.05M $1.367M
YoY Change -4053.55% -89.86%
INVESTING ACTIVITIES
Capital Expenditures $615.0K $145.0K
YoY Change 324.14% -91.87%
Acquisitions
YoY Change
Other Investing Activities -$35.00M -$285.3M
YoY Change -87.73% -142750.0%
Cash From Investing Activities -$35.62M -$285.5M
YoY Change -87.52% 17565.53%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.855M 2.439M
YoY Change -176.06% -37.83%
NET CHANGE
Cash From Operating Activities -54.05M 1.367M
Cash From Investing Activities -35.62M -285.5M
Cash From Financing Activities -1.855M 2.439M
Net Change In Cash -91.52M -281.7M
YoY Change -67.51% -1884.52%
FREE CASH FLOW
Cash From Operating Activities -$54.05M $1.367M
Capital Expenditures $615.0K $145.0K
Free Cash Flow -$54.66M $1.222M
YoY Change -4573.0% -89.55%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001512762
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2021Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
77422970
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
325680000
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
417195000
CY2022Q1 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2021Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2022Q1 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2021Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
76930096
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
77338171
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.24
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.37
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
77253699
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
72832953
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-36721
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
Coherus BioSciences, Inc.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-3615821
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
333 Twin Dolphin Drive
CY2022Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 600
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Redwood City
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94065
CY2022Q1 dei City Area Code
CityAreaCode
650
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
649-3530
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2022Q1 dei Trading Symbol
TradingSymbol
CHRS
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
117039000
CY2021Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
123022000
CY2022Q1 us-gaap Inventory Net
InventoryNet
36945000
CY2021Q4 us-gaap Inventory Net
InventoryNet
37642000
CY2022Q1 chrs Prepaid Manufacturing Expense Current
PrepaidManufacturingExpenseCurrent
13418000
CY2021Q4 chrs Prepaid Manufacturing Expense Current
PrepaidManufacturingExpenseCurrent
13666000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
19361000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10798000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
512443000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
602323000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7998000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7813000
CY2022Q1 us-gaap Inventory Noncurrent
InventoryNoncurrent
59427000
CY2021Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
55610000
CY2022Q1 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
3563000
CY2021Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
3563000
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
9956000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
10025000
CY2022Q1 us-gaap Assets
Assets
593387000
CY2021Q4 us-gaap Assets
Assets
679334000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
21092000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
16159000
CY2022Q1 chrs Accrued Rebates Fees And Reserve Current
AccruedRebatesFeesAndReserveCurrent
71894000
CY2021Q4 chrs Accrued Rebates Fees And Reserve Current
AccruedRebatesFeesAndReserveCurrent
79027000
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
14870000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
22014000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
45892000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
48127000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
153748000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
165327000
CY2022Q1 chrs Term Loans Payable Noncurrent
TermLoansPayableNoncurrent
195849000
CY2021Q4 chrs Term Loans Payable Noncurrent
TermLoansPayableNoncurrent
75513000
CY2022Q1 us-gaap Convertible Subordinated Debt Noncurrent
ConvertibleSubordinatedDebtNoncurrent
224607000
CY2021Q4 us-gaap Convertible Subordinated Debt Noncurrent
ConvertibleSubordinatedDebtNoncurrent
332767000
CY2022Q1 chrs Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
6518000
CY2021Q4 chrs Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
7251000
CY2022Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
102000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
750000
CY2022Q1 us-gaap Liabilities
Liabilities
580824000
CY2021Q4 us-gaap Liabilities
Liabilities
581608000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
77338171
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
76930096
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
7000
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1158766000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1147843000
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-272000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-270000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1145938000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1049854000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
12563000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
97726000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
593387000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
679334000
CY2022Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
60115000
CY2021Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
83034000
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
9370000
CY2021Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
7511000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
82917000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
203492000
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
48753000
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
39391000
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
141040000
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
250394000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-80925000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-167360000
CY2022Q1 us-gaap Interest Expense
InterestExpense
8969000
CY2021Q1 us-gaap Interest Expense
InterestExpense
5648000
CY2022Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-6222000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
32000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
61000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-96084000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-172947000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-96084000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-172947000
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.24
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.37
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
77253699
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
72832953
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-96084000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-172947000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-37000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-96086000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-172984000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
97726000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-96084000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
544000
CY2022Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
2658000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13037000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
12563000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
280974000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-172947000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4429000
CY2021Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
1730000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16982000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-37000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
127671000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-96084000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-172947000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
767000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
849000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
12879000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
16884000
CY2021Q1 us-gaap Gain Loss On Contract Termination
GainLossOnContractTermination
-3210000
CY2022Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
3696000
CY2021Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1001000
CY2022Q1 chrs Upfront License Fee Payments Related To License And Collaboration Arrangements
UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements
35000000
CY2021Q1 chrs Upfront License Fee Payments Related To License And Collaboration Arrangements
UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements
145000000
CY2022Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-6222000
CY2022Q1 chrs Other Noncash Adjustments
OtherNoncashAdjustments
592000
CY2021Q1 chrs Other Noncash Adjustments
OtherNoncashAdjustments
978000
CY2022Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-5991000
CY2021Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-16663000
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2962000
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
11378000
CY2022Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-248000
CY2021Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-2109000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
7632000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4621000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
4757000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
203000
CY2022Q1 chrs Increase Decrease In Accrued Rebates Fees And Reserve
IncreaseDecreaseInAccruedRebatesFeesAndReserve
-7133000
CY2021Q1 chrs Increase Decrease In Accrued Rebates Fees And Reserve
IncreaseDecreaseInAccruedRebatesFeesAndReserve
-3327000
CY2022Q1 chrs Increase Decrease In Accrued Compensation
IncreaseDecreaseInAccruedCompensation
-7144000
CY2021Q1 chrs Increase Decrease In Accrued Compensation
IncreaseDecreaseInAccruedCompensation
-10154000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-3242000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
16897000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-54045000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1367000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
615000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
145000
CY2021Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
140330000
CY2022Q1 chrs Upfront And Milestone Based License Fee Payments Investing Activities
UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities
35000000
CY2021Q1 chrs Upfront And Milestone Based License Fee Payments Investing Activities
UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities
145000000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-35615000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-285475000
CY2022Q1 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
191190000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
544000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4329000
CY2022Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
2658000
CY2021Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1730000
CY2022Q1 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
109000000
CY2022Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
81750000
CY2022Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-181000
CY2021Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-160000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1855000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2439000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-91515000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-281669000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
417635000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
541598000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
326120000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
259929000
CY2022Q1 chrs Product Pipeline Number Of Drug Candidates
ProductPipelineNumberOfDrugCandidates
5
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make judgements, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information. Accounting estimates and judgements are inherently uncertain and therefore actual results could differ from these estimates.</p>
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
417195000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
541158000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
440000
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
440000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
417635000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
541598000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
325680000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
259489000
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
440000
CY2021Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
440000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
326120000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
259929000
CY2021Q4 chrs Reserve For Discounts And Allowances Constitute Variable Consideration
ReserveForDiscountsAndAllowancesConstituteVariableConsideration
109723000
CY2022Q1 chrs Reserve For Sales Discounts And Allowances Constitute Variable Consideration
ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration
146294000
CY2022Q1 chrs Provision Related To Sales Made In Prior Period
ProvisionRelatedToSalesMadeInPriorPeriod
-3146000
CY2022Q1 chrs Payments And Customer Credits Issued From Reserve For Discounts And Allowances Constitute Variable Consideration
PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration
154281000
CY2022Q1 chrs Reserve For Discounts And Allowances Constitute Variable Consideration
ReserveForDiscountsAndAllowancesConstituteVariableConsideration
98590000
CY2020Q4 chrs Reserve For Discounts And Allowances Constitute Variable Consideration
ReserveForDiscountsAndAllowancesConstituteVariableConsideration
123398000
CY2021Q1 chrs Reserve For Sales Discounts And Allowances Constitute Variable Consideration
ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration
170033000
CY2021Q1 chrs Provision Related To Sales Made In Prior Period
ProvisionRelatedToSalesMadeInPriorPeriod
-5027000
CY2021Q1 chrs Payments And Customer Credits Issued From Reserve For Discounts And Allowances Constitute Variable Consideration
PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration
176971000
CY2021Q1 chrs Reserve For Discounts And Allowances Constitute Variable Consideration
ReserveForDiscountsAndAllowancesConstituteVariableConsideration
111433000
CY2021Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
0
CY2022Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
0
CY2022Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2022Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
5317000
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
4870000
CY2022Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
69005000
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
65117000
CY2022Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
22050000
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
23265000
CY2022Q1 us-gaap Inventory Gross
InventoryGross
96372000
CY2021Q4 us-gaap Inventory Gross
InventoryGross
93252000
CY2022Q1 us-gaap Inventory Net
InventoryNet
36945000
CY2021Q4 us-gaap Inventory Net
InventoryNet
37642000
CY2022Q1 us-gaap Inventory Noncurrent
InventoryNoncurrent
59427000
CY2021Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
55610000
CY2022Q1 chrs Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
96372000
CY2021Q4 chrs Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
93252000
CY2022Q1 chrs Prepaid Manufacturing Expense Current
PrepaidManufacturingExpenseCurrent
13400000
CY2022Q1 chrs Prepayments Made To Cmo For Manufacturing Services
PrepaymentsMadeToCmoForManufacturingServices
9000000.0
CY2022Q1 chrs Prepayments Made To Cmo For Other Research And Development Pipeline Program
PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram
4400000
CY2021Q4 chrs Prepaid Manufacturing Expense Current
PrepaidManufacturingExpenseCurrent
13700000
CY2021Q4 chrs Prepayments Made To Cmo For Manufacturing Services
PrepaymentsMadeToCmoForManufacturingServices
8300000
CY2021Q4 chrs Prepayments Made To Cmo For Other Research And Development Pipeline Program
PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram
5400000
CY2021Q1 chrs Inventory Write Off
InventoryWriteOff
3200000
CY2022Q1 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
25614000
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
24662000
CY2022Q1 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
17616000
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
16849000
CY2022Q1 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
7998000
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
7813000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
800000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
800000
CY2022Q1 chrs Accrued Clinical And Manufacturing Liabilities Current
AccruedClinicalAndManufacturingLiabilitiesCurrent
15237000
CY2021Q4 chrs Accrued Clinical And Manufacturing Liabilities Current
AccruedClinicalAndManufacturingLiabilitiesCurrent
30541000
CY2022Q1 chrs Accrued Co Development Costs For Toripalimab Current
AccruedCoDevelopmentCostsForToripalimabCurrent
15115000
CY2021Q4 chrs Accrued Co Development Costs For Toripalimab Current
AccruedCoDevelopmentCostsForToripalimabCurrent
1926000
CY2022Q1 chrs Lease Liabilities Operating And Financing
LeaseLiabilitiesOperatingAndFinancing
3370000
CY2021Q4 chrs Lease Liabilities Operating And Financing
LeaseLiabilitiesOperatingAndFinancing
3492000
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
12170000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
12168000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
45892000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
48127000
CY2022Q1 chrs Collaboration Agreement Option Exercise Fee Per Program
CollaborationAgreementOptionExerciseFeePerProgram
35000000.0
CY2020Q2 us-gaap Share Price
SharePrice
14.815
CY2022Q1 us-gaap Share Price
SharePrice
12.91
CY2022Q1 us-gaap Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year
PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
24824000
CY2022Q1 us-gaap Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
16343000
CY2022Q1 us-gaap Purchase Obligation Due In Second Year
PurchaseObligationDueInSecondYear
911000
CY2022Q1 us-gaap Purchase Obligation Due In Third Year
PurchaseObligationDueInThirdYear
911000
CY2022Q1 us-gaap Purchase Obligation Due In Fourth Year
PurchaseObligationDueInFourthYear
208000
CY2022Q1 us-gaap Purchase Obligation
PurchaseObligation
43197000
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
40693651
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
37997305

Files In Submission

Name View Source Status
0001558370-22-007420-index-headers.html Edgar Link pending
0001558370-22-007420-index.html Edgar Link pending
0001558370-22-007420.txt Edgar Link pending
0001558370-22-007420-xbrl.zip Edgar Link pending
chrs-20220331.xsd Edgar Link pending
chrs-20220331x10q.htm Edgar Link pending
chrs-20220331x10q_htm.xml Edgar Link completed
chrs-20220331xex10d1.htm Edgar Link pending
chrs-20220331xex10d1001.jpg Edgar Link pending
chrs-20220331xex31d1.htm Edgar Link pending
chrs-20220331xex31d2.htm Edgar Link pending
chrs-20220331xex32d1.htm Edgar Link pending
chrs-20220331xex4d5.htm Edgar Link pending
chrs-20220331_cal.xml Edgar Link unprocessable
chrs-20220331_def.xml Edgar Link unprocessable
chrs-20220331_lab.xml Edgar Link unprocessable
chrs-20220331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending